Live feed16:05:00·751dPRReleasevia QuantisnowImmunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024ByQuantisnow·Wall Street's wire, on your screen.IMCR· Immunocore Holdings plcHealth Care
